{"certainAgreement":{"otherDetails":"* Multicenter publication must include input from investigators and Celgene, agreement to be established before publication. It has priority over subset (single center) publication, for duration of 1 year after study completion.\n* Individual investigators have publication right after multicenter publication is complete (or 1 year after study completion), whichever is first. In this case, Celgene has the right to comment and right to ask delay of publication for 180 days.","piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true},"limitationsAndCaveats":{"description":"This study was defined primarily as an expanded access program in the selected countries. Treatment was to continue until disease progression, study drug was discontinued for any reason, or lenalidomide became commercially available for indication."},"pointOfContact":{"email":"clinicaltrialdisclosure@celgene.com","organization":"Celgene Corporation","phone":"1-888-260-1599","title":"Associate Director, Clinical Trials Disclosure"}}